(Q39641996)

English

The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan

scientific article published on 19 October 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 September 2017

The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan (English)

1 reference

Europe PubMed Central

13 September 2017

1 reference

based on heuristic

inferred from title

Patrick A Zweidler-McKay

9

1 reference

Europe PubMed Central

13 September 2017

author name string

Peter E Zage

1

1 reference

Europe PubMed Central

13 September 2017

Timothy C Graham

2

1 reference

Europe PubMed Central

13 September 2017

Lizhi Zeng

3

1 reference

Europe PubMed Central

13 September 2017

Wendy Fang

4

1 reference

Europe PubMed Central

13 September 2017

Christine Pien

5

1 reference

Europe PubMed Central

13 September 2017

Ken Thress

6

1 reference

Europe PubMed Central

13 September 2017

Charles Omer

7

1 reference

Europe PubMed Central

13 September 2017

Jeffrey L Brown

8

1 reference

Europe PubMed Central

13 September 2017

language of work or name

0 references

publication date

19 October 2010

1 reference

Europe PubMed Central

13 September 2017

1 reference

Europe PubMed Central

13 September 2017

117

1 reference

Europe PubMed Central

13 September 2017

6

1 reference

Europe PubMed Central

13 September 2017

1321-1391

1 reference

Europe PubMed Central

13 September 2017

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25674

21 January 2018

Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25674

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25674

21 January 2018

Factors influencing survival in children with recurrent neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25674

21 January 2018

Neurotrophins: roles in neuronal development and function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25674

21 January 2018

Trk receptor tyrosine kinases: a bridge between cancer and neural development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25674

21 January 2018

Mutational analysis of the tyrosine kinome in colorectal cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25674

21 January 2018

Biological effects of TrkA and TrkB receptor signaling in neuroblastoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25674

21 January 2018

Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25674

21 January 2018

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25674

21 January 2018

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25674

21 January 2018

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25674

21 January 2018

Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25674

21 January 2018

Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25674

21 January 2018

Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25674

7 January 2021

based on heuristic

inferred from DOI database lookup

Neurotrophic factors and their receptors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25674

7 January 2021

based on heuristic

inferred from DOI database lookup

Growth, survival and migration: the Trk to cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25674

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25674

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of topotecan for pediatric patients with malignant solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25674

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.25674

1 reference

Europe PubMed Central

13 September 2017

1 reference

Europe PubMed Central

13 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39641996&oldid=1849723117"